Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Respiratory Inhaler Device Market size was valued at USD 38.85 billion in 2024 and is likely to cross USD 71.46 billion by 2037, expanding at more than 4.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of respiratory inhaler device is estimated at USD 40.44 billion.
The growth of the market can be attributed to increasing cases of chronic obstructive pulmonary diseases. Furthermore, the data published by the World Health Organization states that asthma affected 262 million people in 2019 and caused 455,000 deaths worldwide. The inhaled medication can control asthma symptoms, which is the reason global market is projected to grow significantly during the forecast period. Additionally, the prevalence of chronic obstructive pulmonary diseases is directly related to tobacco smoking. The data released by the Institutes for Health Metrics and Evaluation states that the number of smokers is rising worldwide and in 2019, smoking caused 8 million deaths. On the back of an escalating number of people involved in smoking the market is estimated to grow significantly during the forecast period. The inhalers are effective in providing relief to common cold patients. On account of the efficacy in providing relief to common cold patients, the respiratory inhaler device market is projected to grow during the forecast period.
Respiratory Inhaler Device Sector: Growth Drivers and Challenges
Growth Drivers
-
Rising Air Pollution
- Growing Cases of Asthma
- Increasing Patients with Chronic Obstructive Pulmonary Disease
Challenges
-
Associated Side-Effects
Respiratory Inhaler Device Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.8% |
|
Base Year Market Size (2024) |
USD 38.85 billion |
|
Forecast Year Market Size (2037) |
USD 71.46 billion |
|
Regional Scope |
|
Respiratory Inhaler Device Segmentation
The respiratory inhaler device market is segmented by disease indication into asthma, chronic obstructive pulmonary disease, pulmonary disease, and others. Out of which, the asthma sub-segment is anticipated to hold the largest share in the global market on account of the aggressively increasing number of patients with asthma. Respiratory inhalers are highly effective in controlling asthma symptoms.
Our in-depth analysis of the global respiratory inhaler device market includes the following segments:
|
Product |
|
|
Technology |
|
|
Disease Indication |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Respiratory Inhaler Device Industry - Regional Synopsis
Regionally, the global respiratory inhaler device market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is predicted to dominate majority revenue share by 2037, on the back of presence of a highly established healthcare infrastructure. Furthermore, the Centers for Disease Control and Prevention states that chronic obstructive pulmonary diseases affect more than 15 million Americans. Owing to this, the global market is projected to witness remarkable growth during the forecast period. Apart from this, a report published by the National Center for Biotechnology Information states that 5% of adults suffer from acute bronchitis every year. A person suffering from bronchitis might receive a nebulizer breathing treatment which calms the inflation in the mucous membrane and allow the body to start to heal.
The Asia Pacific region is also estimated to witness significant growth during the forecast period on the back large number of people suffering from respiratory diseases. Also, the data released by the WHO, countries such as, Bangladesh, India, and Pakistan are among the most polluted countries in the world, all exceeding WHO guidelines by 10 times. The increasing air pollution in the region is leading to severe respiratory diseases among the population, which is the reason the global respiratory inhaler device market is projected to witness significant growth during the forecast period.
Companies Dominating the Respiratory Inhaler Device Landscape
- Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Beximco Pharmaceuticals Ltd.
- Omron Healthcare Europe B.V
- Boehringer Ingelheim International GmbH
- Merck & Co., Inc.,
- GlaxoSmithKline plc.
- Cipla Inc.
- Koninklijke Philips N.V.,
- PARI GmbH
- AstraZeneca plc
Recent Developments
-
December 12, 2021: PetMedix, a UK based research, and development stage biopharmaceutical company joins hand with Boehringer Ingelheim to develop animal antibody therapeutics.
- Report ID: 202
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Respiratory Inhaler Device Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
